Lilly Claims It’s On Pace To Traverse Its Patent Cliff, Meet Financial Guidance Through 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
As it prepares for the U.S. patent expiration of blockbuster antidepressant Cymbalta later this year, Lilly says it is meeting three strategic priorities it set in 2009, putting it on a path to return to sustainable growth.
You may also be interested in...
Lilly Gives Investors A Glimpse At Post-2014 Balance Sheet
Eli Lilly says R&D and SG&A spending will decline as a percent of sales post-2014, likely resulting in spending cuts, when the company expects to return to sales growth after cycling through important patent losses.
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.